Basimglurant is under clinical development by Noema Pharma and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Basimglurant’s likelihood of approval (LoA) and phase transition for Trigeminal Neuralgia (Tic Douloureux) took place on 20 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Basimglurant Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Basimglurant overview

Basimglurant (RG7090, RO4917523, R7090) is under development for the treatment of stuttering, seizures associated with tuberous sclerosis complex (TSC) and for the management of pain associated with trigeminal neuralgia (TN).  Basimglurant is a mGluR5 (metabotropic glutamate receptor 5) antagonist.

It was also under development for the treatment of treatment-resistant depression, anxiety, major depressive disorder and fragile X syndrome. The drug candidate is administered orally.

Noema Pharma overview

Noema Pharma (Noema) is a biotechnology company that discovers and develops treatment for orphan diseases of brain and central nervous system. The company is developing NOE-101, a mGluR5 inhibitor for treatment of tuberous sclerosis complex (TSC) and severe pain in trigeminal neuralgia (TN). It is also investigating NOE-105, a PDE10A inhibitor that modulates dopamines D2 receptors to treat tourette syndrome. The company was funded by Sofinnova Partners, Glide healthcare, Invus, Roche, BioMed Partners and Polaris Partners. Noema is headquartered in Basel, Basel-Stadt, Switzerland.

Quick View Basimglurant LOA Data

Report Segments
  • Innovator
Drug Name
  • Basimglurant
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Genetic Disorders
Key Developers
  • Sponsor Company: Noema Pharma
  • Originator: F. Hoffmann-La Roche
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.